We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Generic drugmakers planning to copy Dr. Reddy’s Laboratories’ strategy of marketing near-equivalent versions of brand drugs years before the basic patent expires will have to devise another plan after a recent appeals court ruling effectively ended Dr. Reddy’s challenge to Pfizer’s top-selling hypertension drug Norvasc, according to industry analysts.
In a move that will likely delay the start of trials by at least seven months, Aventis has filed additional patent infringement claims against five generic firms challenging the drugmaker’s top-selling allergy products Allegra (fexofenadine HCl) and Allegra-D (fexofenadine HCl 60-mg/pseudoephedrine HCl 120-mg).
Purdue Pharma is facing an antitrust lawsuit by two health insurers that allege the firm blocked generic competition on its pain treatment OxyContin (oxycodone).
Drugmakers looking to replicate Dr. Reddy’s Laboratories’ strategy of marketing near-equivalent versions of brand drugs years before the basic patent expires will have to put their plans on hold after a recent appeals court ruling effectively ended Dr. Reddy’s challenge to Pfizer’s top-selling hypertension drug Norvasc, according to industry analysts.
Drug giant Pfizer has filed a patent infringement lawsuit against generic firm Teva Pharmaceuticals over its bid to market a version of Pfizer’s top-selling arthritis drug Celebrex (celecoxib).
Generic firms hoping to replicate Dr. Reddy’s Laboratories’ strategy of marketing near-equivalent versions of brand drugs years before the basic patent expires will have to put their plans on hold after a recent appeals court ruling effectively ended Dr. Reddy’s challenge to Pfizer’s top-selling hypertension drug Norvasc, according to industry analysts who have reviewed the ruling.
Drugmaker Atrix Laboratories has received a stay postponing a patent infringement fight over its prostate cancer drug Eligard (leuprolide acetate) injectable suspension, the firm said Friday.
The Pfizer-Dr. Reddy’s patent litigation involving Pfizer’s Norvasc antihypertensive treatment may be a signal to the brand industry that patent extensions cover a broader area, giving them more protection against generic competition, according to legal experts who have been analyzing the case for the past week.